Chapter 43 — Key Takeaways

Enhancement Outside the Clinic: Work, Sport, Military, and the Coercion Question

The one-sentence version

Enhancement is the same molecule with the clinical structure removed — no diagnosis, no indication, no clinician with a duty, no individualized risk-benefit judgment — and the hardest problem it creates is not safety but coercion, because an enhancement adopted widely enough in a positional contest stops being an advantage and becomes a baseline that nobody chose.

The structural point (§43.1)

• Clinical medicine supplies four things: a diagnosis, an indication, a clinician who owes the patient a duty, and a risk-benefit judgment made under that duty for a specific person. Enhancement removes all four and keeps the molecule.
• The list is an inventory, not a scorecard. Absences are not automatically wrongs. The point is that people comparing enhancement to clinical use usually compare only the molecule — the one element that does not vary.
• Because the enhancement user makes their own risk-benefit judgment, its quality is limited by the quality of their information — which arrives through the Chapter 6 pipeline, at its most degraded, with nobody present to say that study was in rats.
• The compounds most available for enhancement are systematically those with the least human safety data. Not coincidence: cheap synthesizability, an accepted injection route, and the absence of a generic name are all downstream of never having completed clinical development.

The workplace (§43.2)

• Where advancement is relative rather than absolute, an enhancement adopted by some becomes a cost imposed on all. Nobody has to act badly; ranked contests convert others' improvement into your decline.
• The well-documented literature on workplace pharmacological enhancement concerns stimulants, not peptides. Peptide use in this context is not well characterized, and this book refuses to supply a prevalence figure it cannot source.
• Susceptibility rises with observable comparable output, short decisive windows, and no testing combined with norms of silence.
• Misperception does real work. Believing competitors are enhanced produces pressure whether or not the belief is true — which means a compound with no real effect can still generate real spending and real risk exposure.

Sport (§43.3)

• Chapter 38 owns the rules. This chapter owns one point: sport is the only domain with an explicit, enforced, adjudicated answer, which makes it the only real evidence about what such an answer costs and achieves.
• Achieves: a known published standard, stated criteria, an exemption route for genuinely ill participants, deterrence, and a body of adjudicated decisions.
• Costs: a large permanent apparatus, intrusion no other profession accepts, unintentional violations from contaminated supply, a permanent detection lag, and an access gradient inside the exemption mechanism itself.
• Anyone proposing an enforced answer elsewhere should be asked whether they have thought as hard as anti-doping has, and why they expect a better result.

Institutional contexts (§43.4)

• An institution that can order can also pressure, and "voluntary" means something thinner inside a hierarchy — even when everyone involved is acting in good faith.
• The chapter deliberately asserts nothing about current practice in any specific institution, because such claims cannot be sourced to the book's standard. The alternative to abstraction was invention.
• The institutional interest can be entirely legitimate. The coercion problem does not require bad motives, which is why it cannot be fixed by improving motives.

The coercion question (§43.5) — the chapter's core

• An enhancement adopted by enough people stops being an advantage and becomes a baseline.
• Five steps: positional contest → early adoption for advantage → non-adopters decline without doing anything → defensive adoption to avoid a loss → new baseline where the advantage is dissipated and only the cost remains.
• Step 4 is the hinge. Same action, different reason: seeking a gain versus avoiding an imposed loss.
• Nobody has to compel anything. The structure emerges from adoption alone. It is a collective action problem, and exhortation does not solve those.
• Applies weakly where the benefit is private and absolute, performance is unobservable, or the contest is non-positional. Applies strongly where competition is explicitly relative, performance is measured and compared, the enhancement is cheap and concealable, and harms are delayed.
• A coercive structure built on a false efficacy belief is worse, not better — everything from step 3 onward still happens, with an empty benefit column.

The level playing field (§43.6)

• Strongest form: prohibition relocates supply to an unregulated market with documented failures of identity, concentration, and sterility; a sanctioned regime supplies supervision, verified product, adverse-event reporting, and honest disclosure. This is the harm-reduction argument and it has a real record elsewhere.
• Strongest objections: it does not address coercion at all; it transfers risk to people who declined; availability is never actually equal in any implemented system; it treats supervision as a substitute for evidence; and the harm-reduction evidence base comes from domains where the exposed population was not being enlarged.
• The book does not resolve it — the weights are values, not findings. But note that the argument is far stronger as a safety argument than as a fairness argument, and is almost always deployed as the latter.

Safety without a physician (§43.7)

• Supervision provides baselines, targeted monitoring, dose adjustment, recognizing tolerance rather than escalating into it, interaction checking, differential diagnosis, and someone to call.
• In enhancement contexts none of it is present by construction — and non-disclosure to the clinicians who are involved is itself a safety failure.
• Highest uncertainty, lowest oversight — and the two share a cause. The regulatory absence that makes a compound available is the same absence that means nobody generated safety data or wrote monitoring guidance.
• Chapter 16's mass without function result is the anchor: a visible, measurable, subjectively convincing effect coexisting with no functional benefit. It is why "I could tell it was working" is not evidence about what people think it is evidence about.

Risk and benefit (§43.8)

• The individual bears the physiological risk; the employer, team, or institution captures much of the performance benefit.
• Where risk and benefit separate, the party bearing the risk is systematically under-compensated. This is an externality argument from economics and does not depend on any moral premise — it holds whatever you concluded about permissibility.
• Sharpened here by invisibility, unattributability ("you cannot be compensated for a harm nobody can attribute"), relationships that end before exposures do, and the total absence of the compensation structures we built for every other occupational hazard.

What would make it defensible (§43.9)

1. Established safety at the relevant exposure — in healthy people, at the exposures actually used, for the durations actually used.
2. Genuine informed consent — real information and a real alternative.
3. Absence of coercive structure — non-adopters not made worse off.
4. Risk borne by the beneficiary — through compensation, liability, monitoring, or insurance.
5. Reversibility — because reversible decisions tolerate bad information and irreversible ones do not.

• Cumulative, not alternative. Most current cases meet at most one or two of five.
• That is a statement about the present state of evidence and structure, not a permanent verdict.
• Conditions 1 and 5 could be satisfied by research; 4 by policy; 2 partly by better information. Condition 3 cannot be satisfied by any of them, because it is a property of the contest rather than of the person, the compound, or the seller.

The ratings

What to carry forward

A claim confirmed by every possible outcome is not a prediction; it is an attitude. That test applies to social claims exactly as it applies to pharmacological ones, and it is the skill Chapter 44 will need most.

And the one line worth memorizing: condition 3 is a property of the contest, not of the person, the compound, or the seller. It is the only part of this that no individual can solve by being careful.